Skip to main content
. 2013 Aug 1;21(10):2925–2932. doi: 10.1007/s00520-013-1911-7

Fig. 1.

Fig. 1

Pooled analysis of post-approval studies of Zarzio® in patients with cancer undergoing cytotoxic chemotherapy: most frequent solid tumours and haematological malignancies (n = 1,302)